titrated to 400 mg daily. His PANSS score dropped to 83. However, following generalized tonic-clonic seizures at clozapine 450 mg daily, the drug was reduced to 200 mg daily. Valproate was added and titrated to 1000 mg daily. After a normal EEG, his clozapine was increased, but owing to marked sedation, the drug was again reduced to 200 mg daily. Because the patient's psychopathology had worsened (his PANSS score increased to 102), risperidone was subsequently added and titrated to 6 mg daily. Simultaneously, Mr C underwent CBT with 2 procedures: 1) belief modification by way of verbal challenge and reality testing for delusions (4) and 2) normalizing his rationale for auditory hallucinations and somatic passivity (5) . Sessions were weekly and lasted 20 to 40 minutes.
Two months of this combined therapy saw Mr C's PANSS score dropping to 59 (reduced by 54% from intake). His cognitive functioning, including attention, memory, and judgement, also improved. Notably, after starting CBT, his conviction regarding his delusions decreased, as did his preoccupation with somatic passivity and auditory hallucinations. The CBT was then shifted to oncemonthly sessions, and the patient maintained this improvement at his last follow-up, 6 months later.
This report underscores the effectiveness of combined pharmacotherapy and psychotherapy in managing treatmentresistant schizophrenia, especially for patients in whom an initial good response to clozapine is curtailed by subsequent clozapine-induced seizures.
Although it might be difficult to segregate the individual effects of AAs and CBT, these 2 modalities may be complementary, especially because they both bring about cognitive rehabilitation in patients with schizophrenia. The realm of cognitive rehabilitation includes 2 general components (6) . First, specific deficits in attention, cognitive flexibility, and vigilance must be treated. These deficits are improved by AAs (3). Second, specific thought-content difficulties, such as hallucinations, delusions, and medication compliance, must be dealt with. These difficulties are addressed by CBT (2) . Interestingly, clozapine and risperidone may in turn be complementary in improving cognitive deficits: clozapine improves attention and reaction time, while risperidone improves memory and concept formation (3) .
It may also be speculated that AAs potentiate CBT. CBT in part reduces symptomatology by decreasing the salience of old learning and involving new, alternative appraisals, which requires intact learning processes; risperidone and olanazpine improve memory function, including new learning (3, 7) . Further validation of these observations in a systematic study comparing combined treatment with AAs alone is encouraged.
Distress Levels in Patients With Premenstrual Dysphoric Disorder
Dear Editor:
It is estimated that 75% of women of reproductive age experience premenstrual syndrome (PMS) (1), which includes emotional, physical, and behavioural changes. However, only 3% to 8% experience premenstrual dysphoric disorder (PMDD) (2)-severe premenstrual mood symptoms that interfere with normal daily functioning (work, social activities, and relationships) (3). The chronological relation of symptoms and the menstrual cycle has been investigated (4), as have been medications and lifestyle modifications for PMS and PMDD (2) . The effect of medication on psychosocial functioning in PMDD patients has also been evaluated (5, 6) , but few studies have systematically looked at the impact of symptoms on lifestyle and daily functioning in subjects with PMDD, compared with control subjects (7) .
Daily self-rating forms that record symptoms and severity are widely used to confirm the diagnosis of PMS or PMDD, but there are no specific questionnaires to measure psychosocial functioning in PMDD (7) . Therefore, we studied levels of distress, degrees of impairment, and impact on lifestyle in women with PMDD, compared with a control group. We used 3 validated self-rating scales: the Symptom Questionnaire (SQ) (8), the Sheehan Disability Scale (9) , and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form (10) as applied to premenstrual symptoms. Subjects diagnosed with PMDD (n = 15) and control subjects (n = 15) gave written informed consent and completed the self-rating questionnaires (once only) during the luteal phase. They also reported general demographic data and menstrual history. We conducted independent t-tests to determine the effect of PMDD as measured by the self-rating scales; preliminary findings show significant between-group differences in the mean total scores of distress levels, functional impairment, and quality of life.
Our study results indicate that women with PMDD report more distress and impairment and less satisfaction during the luteal phase, compared with the control subjects. However, these results should be viewed with caution, because there were few participants, the questionnaires were only completed once, and the measures were not designed specifically for PMDD. The study also did not take into account unusual current stressors that might have magnified symptom severity and possibly influenced the self-rating scores. These study findings, however, do suggest that the impact of PMDD on psychosocial functioning can be measured systematically by self-rating questionnaires. The preliminary results of the SQ support the view that mood symptoms, and not physical symptoms, characterize women with PMDD (2) and that there is a correlation between psychosocial functioning and the mood symptoms (4) measured by these 3 questionnaires.
Prospective daily charting of symptoms is crucial to establish the diagnosis of PMDD, but measuring psychosocial functioning may also help to confirm severity and assist in treatment recommendations (for example, medication, lifestyle changes, or alternative therapies). We encourage a larger study using accepted, standardized ratings of psychosocial functioning in relation to PMDD.
Annie J Kuan, BA Diana MG Carter, MD, CRCPC Fred J Ott, OT Vancouver, British Columbia
Alcoholism, Seasonal Depression, and Suicidal Behaviour
Several studies in different countries have reported a high prevalence of alcohol-use disorders among people who commit suicide (for example, 56% in New York [1] and 43% in Northern Ireland [2] ). Such figures far exceed the prevalence of alcohol-use disorders in the general population (3, 4) . Because comorbid alcoholism and depression are associated with increased suicidality (5) , global suicide prevention strategies should include a focus on alcohol-use disorders that aggressively treats comorbid depression (3).
Seasonal affective disorder (SAD), a condition wherein depressions in fall and winter alternate with periods of no depression in the spring and summer, is one of the most treatable causes of suicidal behaviour. Further, recent data suggest that seasonal depression is closely related to alcoholism (6, 7) , and some patients with alcoholism have a seasonal pattern to their alcohol abuse. These patients may be self-medicating SAD with alcohol. Family studies also suggest a relation between alcoholism and SAD (7, 8) . It has been proposed that if some patients with alcoholism attempt to self-medicate SAD with alcohol, or if SAD predisposes this population to alcohol relapse, then treatment of SAD with light therapy may help to prevent alcohol relapse (7) . Although suicidal ideation occurs less frequently in patients with SAD than in those with nonseasonal depression (9), suicidal ideas are nonetheless commonly found in this population (9) . SAD can be effectively treated with light therapy that relieves suicidal ideation, consistent with overall clinical improvement. Thus, light therapy for patients with SAD might both decrease suicidal ideation and prevent relapse into alcoholism. Worsening suicidal ideation is uncommon in patients treated with morning light therapy. However, clinicians should always be vigilant for symptoms of suicidality. In addition, pharmacologic and psychological treatments can help SAD patients who abuse alcohol. Contemporary treatment may prevent suicidal behaviour in patients with comorbid SAD and alcoholism.
